1. Home
  2. LOAN vs SNTI Comparison

LOAN vs SNTI Comparison

Compare LOAN & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LOAN
  • SNTI
  • Stock Information
  • Founded
  • LOAN 1989
  • SNTI 2016
  • Country
  • LOAN United States
  • SNTI United States
  • Employees
  • LOAN N/A
  • SNTI N/A
  • Industry
  • LOAN Real Estate Investment Trusts
  • SNTI Biotechnology: Pharmaceutical Preparations
  • Sector
  • LOAN Real Estate
  • SNTI Health Care
  • Exchange
  • LOAN Nasdaq
  • SNTI Nasdaq
  • Market Cap
  • LOAN 50.7M
  • SNTI 53.6M
  • IPO Year
  • LOAN 1999
  • SNTI N/A
  • Fundamental
  • Price
  • LOAN $4.49
  • SNTI $1.77
  • Analyst Decision
  • LOAN
  • SNTI Strong Buy
  • Analyst Count
  • LOAN 0
  • SNTI 3
  • Target Price
  • LOAN N/A
  • SNTI $9.67
  • AVG Volume (30 Days)
  • LOAN 43.3K
  • SNTI 91.7K
  • Earning Date
  • LOAN 10-24-2025
  • SNTI 11-13-2025
  • Dividend Yield
  • LOAN 10.36%
  • SNTI N/A
  • EPS Growth
  • LOAN N/A
  • SNTI N/A
  • EPS
  • LOAN 0.46
  • SNTI N/A
  • Revenue
  • LOAN $7,138,128.00
  • SNTI N/A
  • Revenue This Year
  • LOAN N/A
  • SNTI N/A
  • Revenue Next Year
  • LOAN $4.47
  • SNTI $150.00
  • P/E Ratio
  • LOAN $9.59
  • SNTI N/A
  • Revenue Growth
  • LOAN N/A
  • SNTI N/A
  • 52 Week Low
  • LOAN $4.29
  • SNTI $1.26
  • 52 Week High
  • LOAN $6.05
  • SNTI $16.94
  • Technical
  • Relative Strength Index (RSI)
  • LOAN 24.60
  • SNTI 49.15
  • Support Level
  • LOAN $4.29
  • SNTI $1.44
  • Resistance Level
  • LOAN $4.98
  • SNTI $1.99
  • Average True Range (ATR)
  • LOAN 0.15
  • SNTI 0.18
  • MACD
  • LOAN -0.04
  • SNTI -0.03
  • Stochastic Oscillator
  • LOAN 19.06
  • SNTI 57.32

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

About SNTI Senti Biosciences Inc.

Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.

Share on Social Networks: